ANCA and anti-glomerular basement membrane double-positive patients : A systematic review of the literature
Copyright © 2021 Elsevier B.V. All rights reserved..
INTRODUCTION: Double-positive patients (DPP) exhibiting anti-glomerular basement membrane (GBM) and anti-neutrophil cytoplasmic antibodies (ANCAs) belong to an entity that is newly and poorly described, mainly in short series. We aimed to better characterize the epidemiological features, clinical presentation and therapeutic outcomes of these patients through a systematic review.
METHODS: We performed a systematic review of English-, German-, Spanish- and French-written publications from February 1987 to March 2020 reporting cases of DPP using the following databases: PubMed, Scielo, ScienceDirect, Google Scholar, The Cochrane Library, Open Grey, The Grey Literature Report, Clinicaltrials.gov and International Clinical Trial Registry Platform of the World Health Organization.
RESULTS: In total, 538 DPP were identified from 90 articles. Their clinical presentations were often severe, and the majority exhibited acute kidney failure (91.8%) with a median initial serum creatinine level of 873 μmol/L; 50.7% had alveolar haemorrhage. Other manifestations were present in 30.3% of DPP, mainly ear, nose, throat and articular manifestations. ANCAs were predominantly directed against MPO (n = 377/523; 72.1%) compared to PR3 (n = 107/523; 20.5%), with rare cases of triple positivity (n = 15/538; 2.9%). Although most patients received initial immunosuppressive therapy (n = 285/317; 89.9%), the one-year overall, renal and relapse-free survival rates were 64.8%, 38.7% and 71.1%, respectively.
CONCLUSION: DPP are associated with the characteristics of two eponymous vasculitis types, responsible for a poor overall and renal prognosis. Thus, simultaneous testing of both antibodies and systematic renal biopsy should be recommended in every patient with rapidly progressive glomerulonephritis to recognize this difficult-to-treat and rare disease.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Autoimmunity reviews - 20(2021), 9 vom: 15. Sept., Seite 102885 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Philip, Rémi [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 18.08.2021 Date Revised 18.08.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.autrev.2021.102885 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM327887060 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM327887060 | ||
003 | DE-627 | ||
005 | 20231225201756.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.autrev.2021.102885 |2 doi | |
028 | 5 | 2 | |a pubmed24n1092.xml |
035 | |a (DE-627)NLM327887060 | ||
035 | |a (NLM)34242834 | ||
035 | |a (PII)S1568-9972(21)00158-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Philip, Rémi |e verfasserin |4 aut | |
245 | 1 | 0 | |a ANCA and anti-glomerular basement membrane double-positive patients |b A systematic review of the literature |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.08.2021 | ||
500 | |a Date Revised 18.08.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
520 | |a INTRODUCTION: Double-positive patients (DPP) exhibiting anti-glomerular basement membrane (GBM) and anti-neutrophil cytoplasmic antibodies (ANCAs) belong to an entity that is newly and poorly described, mainly in short series. We aimed to better characterize the epidemiological features, clinical presentation and therapeutic outcomes of these patients through a systematic review | ||
520 | |a METHODS: We performed a systematic review of English-, German-, Spanish- and French-written publications from February 1987 to March 2020 reporting cases of DPP using the following databases: PubMed, Scielo, ScienceDirect, Google Scholar, The Cochrane Library, Open Grey, The Grey Literature Report, Clinicaltrials.gov and International Clinical Trial Registry Platform of the World Health Organization | ||
520 | |a RESULTS: In total, 538 DPP were identified from 90 articles. Their clinical presentations were often severe, and the majority exhibited acute kidney failure (91.8%) with a median initial serum creatinine level of 873 μmol/L; 50.7% had alveolar haemorrhage. Other manifestations were present in 30.3% of DPP, mainly ear, nose, throat and articular manifestations. ANCAs were predominantly directed against MPO (n = 377/523; 72.1%) compared to PR3 (n = 107/523; 20.5%), with rare cases of triple positivity (n = 15/538; 2.9%). Although most patients received initial immunosuppressive therapy (n = 285/317; 89.9%), the one-year overall, renal and relapse-free survival rates were 64.8%, 38.7% and 71.1%, respectively | ||
520 | |a CONCLUSION: DPP are associated with the characteristics of two eponymous vasculitis types, responsible for a poor overall and renal prognosis. Thus, simultaneous testing of both antibodies and systematic renal biopsy should be recommended in every patient with rapidly progressive glomerulonephritis to recognize this difficult-to-treat and rare disease | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a ANCA-associated vasculitis | |
650 | 4 | |a Anti-GBM disease | |
650 | 4 | |a Anti-GBM vasculitis | |
650 | 4 | |a Double-positive vasculitis | |
650 | 4 | |a Systematic review | |
650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
650 | 7 | |a Autoantibodies |2 NLM | |
700 | 1 | |a Dumont, Anael |e verfasserin |4 aut | |
700 | 1 | |a Martin Silva, Nicolas |e verfasserin |4 aut | |
700 | 1 | |a de Boysson, Hubert |e verfasserin |4 aut | |
700 | 1 | |a Aouba, Achille |e verfasserin |4 aut | |
700 | 1 | |a Deshayes, Samuel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 20(2021), 9 vom: 15. Sept., Seite 102885 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2021 |g number:9 |g day:15 |g month:09 |g pages:102885 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2021.102885 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2021 |e 9 |b 15 |c 09 |h 102885 |